Tue, May 13, 9:00 PM (30 days ago)
**Summary of REMSleep Holdings, Inc. (RMSL) Q1 2025 Financial Performance** **Company Overview:** REMSleep Holdings, Inc. (RMSL) focuses on developing and distributing products to help people affected by sleep apnea. The company's primary product is the DeltaWave CPAP interface, designed to improve comfort and compliance for sleep apnea patients. **Financial Health and Performance:** - **Revenue:** No revenue was recognized in Q1 2025. In Q1 2024, revenue was $57,881, with a cost of goods sold of $13,590, resulting in a gross margin of $44,291. - **Profit Margins:** The company reported a net loss of $85,488 in Q1 2025, compared to a net loss of $252,580 in Q1 2024. The improvement in net loss is attributed to reduced operating expenses and gains from derivative liabilities. - **Cash Flow:** Cash used in operating activities was $110,096 in Q1 2025, slightly lower than the $113,475 used in Q1 2024. The company received $154,000 from the issuance of convertible notes in Q1 2025, compared to $125,000 in Q1 2024. - **Earnings Changes:** The net loss per share remained at $0.00 for both periods due to the significant number of outstanding shares. - **Operating Expenses:** Total operating expenses decreased by $37,191, from $168,506 in Q1 2024 to $131,315 in Q1 2025. This reduction is primarily due to lower general and administrative expenses, development expenses, and lease expenses. - **Future Operations Impact:** The company's ability to continue as a going concern is uncertain due to recurring losses and the need for additional financing. Management plans to obtain funding from new investors and implement a plan to generate sales. **Trends and Uncertainties:** - **Product Development:** The company has completed the development and testing of the DeltaWave product and expects to have inventory ready for the market in Q2 2025. - **Financing:** REMSleep Holdings, Inc. relies on debt and equity financing to support its operations. The company issued multiple convertible notes in Q1 2025, indicating a continued need for external funding. - **Market Risks:** The company faces significant competition in the sleep apnea market and must generate sufficient revenues or raise additional capital to ensure its viability. **Conclusion:** REMSleep Holdings, Inc. is in a critical phase, focusing on commercializing its DeltaWave product while addressing significant financial challenges. The company's ability to secure additional financing and generate sales will be crucial for its future success.